Spravato®

Are you struggling with treatment-resistant depression? Have traditional antidepressants and therapies failed to provide the relief you need? At Awen, we offer a groundbreaking treatment option that could be the answer you've been looking for: Spravato® (esketamine) nasal spray.

Schedule an Appointment

What is Spravato®?

Spravato® is an FDA-approved treatment specifically designed for adults with treatment-resistant depression. Unlike traditional antidepressants, Spravato® works quickly to reduce depressive symptoms by targeting different pathways in the brain. Administered as a nasal spray, Spravato® can be used in conjunction with an oral antidepressant or as monotherapy under the close supervision of our experienced healthcare professionals.

Rapid Acting

Effects often seen within the first few treatments

Breakthrough Option

For those who haven't responded to traditional treatments

Comprehensive Relief

Improves mood, energy, and reduces suicidal thoughts

How Does Spravato® Work?

Spravato targets the glutamate system, a critical brain pathway for learning, emotion, and memory. It acts by:

  • Blocking NMDA receptors- Promoting a burst of glutamate

  • Activating AMPA receptors- Leading to increased BDNF and synaptic growth

  • Enhancing neuroplasticity- our brain's ability to rewire and heal

  • Supporting rapid recovery- In brain areas affected by chronic depression

Spravato offers both biological and psychological relief, working alongside your oral antidepressant.

Who Qualifies for Spravato®?

Spravato is approved for:

  • Adults with Treatment-Resistant Depression (TRD)

  • Patients with Major Depressive Disorder and suicidal thoughts or behavior.

What is TRD?

  • TRD is defined as depression that hasn't responded to at least two antidepressants, each taken at an adequate dose and duration.

  • Approximately 30% of patients with depression meet TRD criteria.

Treatment Schedule

Induction Phase (1 - 4 Weeks):

  • Twice per week sessions

  • Each visit lasts 2 hours (includes administration and observation)

Maintenance Phase:

  • Week 5 to Week 8: Once weekly

  • After 9+ weeks: Once every 2 weeks (based on clinical response)

Treatment Process

1- Comprehensive Evaluation: Our providers perform a psychiatric assessment to ensure Spravato is the right fit for your diagnosis and treatment history.

2- Prior Authorization & Insurance Navigation: We handle both pharmacy and medical benefit submissions:

  • Pharmacy Benefit: Covered by most commercial insurers

  • Medical Benefit: Accepted by some plans—we'll confirm eligibility

    Our team assists with documentation and insurance approval

3- In-Clinic Administration: Spravato is administered under supervision in our clinic, with private, calm treatment rooms and continuous monitoring by trained staff.

Why Choose Awen?

  • Certified Spravato Treatment Center

  • Fully certified and trained in Spravato administration

  • Insurance Coordination & Prior Auth Support

  • We handle all insurance paperwork and approvals

  • Safe, Comfortable Clinical Setting

  • Patient rooms with continuous monitoring

  • Experienced Providers

  • Specialists in TRD and ketamine-based care

Spravato® FAQs

  • Unlike traditional antidepressants that can take 4-6 weeks to show effects, many patients notice improvements with Spravato within the first few treatments. The rapid-acting nature of esketamine allows for quicker symptom relief, particularly for patients with treatment-resistant depression.

  • Common side effects include mild dizziness, nausea, and occasionally headaches. These effects are typically temporary and occur during or shortly after treatment. Our clinical team monitors you closely and can provide strategies to manage any discomfort. Most patients find the side effects tolerable given the significant benefits.

  • Initially, you'll receive Spravato twice weekly for the first month, then once weekly for the second month, and then every other week or weekly for maintenance. Each session takes about 2 hours in our clinic, including the observation period after administration.

  • Spravato is FDA-approved for adults with treatment-resistant depression—meaning you've tried at least two different antidepressants without adequate response. It's also approved for adults with major depressive disorder who have acute suicidal ideation or behavior.

  • Most commercial insurance plans cover Spravato, and we handle all prior authorization paperwork. We work with both pharmacy and medical benefits to ensure you get the coverage you deserve. Our team will verify your specific coverage and help navigate any insurance requirements.

  • Your first session begins with a comprehensive evaluation. The nasal spray is self-administered under our supervision in a private, comfortable treatment room. You'll be monitored for about 2 hours afterward.

Take the First Step Toward Relief

At Awen, we are committed to providing compassionate, cutting-edge care for those battling treatment-resistant depression. If you or a loved one is struggling with depression that hasn’t responded to other treatments, Spravato® could be the breakthrough you’ve been waiting for.

Contact us today to schedule a consultation and learn more about how Spravato® can help you reclaim your life from depression.

*Spravato® is a prescription medication used in combination with an oral antidepressant to treat adults with treatment-resistant depression. This treatment is only available under the supervision of a healthcare professional in a certified treatment center.*

Questions about Spravato®?

Let us know! Use the form below for inquiries about Spravato®.

Spravato® Referral Form Download